Dallas Nephrology Associates Named 2025 Acclaim Award Honoree by the American Medical Group Association

Dallas Nephrology Associates (DNA) is proud to announce its recognition as a 2025 Acclaim Award Honoree by the American Medical Group Association (AMGA). This prestigious award was presented to DNA during AMGA’s Annual Conference at the Gaylord Texan Resort & Convention Center in Grapevine, TX, on March 28, 2025. The recognition marks DNA’s second award by a leading national organization in the last year, highlighting the organization’s work in the field of value-based care as an independent specialist practice.

The Acclaim Award honors excellence and innovation within high-performing medical groups and health systems. It specifically recognizes organizations that are working to advance organizations closer to the “ideal” medical group and health system. DNA’s value-based model is one that prioritizes a proactive, efficient, patient-focused approach to better manage patients with chronic kidney disease. This framework is built upon the principles of the Quadruple Aim, which focuses on improving patient care, reducing costs, improving patient health, and enhancing the experience of care providers.

Dr. Alexander Liang, president and CEO of DNA, expressed his pride in receiving this distinguished award. "Being included among the esteemed recipients of the Acclaim Award is a testament to our ongoing commitment to excellence and quality, patient-centered care," said Dr. Liang. "This recognition reinforces our dedication to providing the best possible care for our patients, while continually innovating within the healthcare system to improve outcomes for all."

DNA’s value-based care model, which emphasizes “patient-centered care” through education and collaborative treatment plans, has been instrumental in driving improved patient outcomes and reducing overall healthcare costs. This approach aligns with AMGA’s mission to transform healthcare delivery and provide more effective, efficient, and equitable care to patients nationwide.

The Acclaim Award recognition is another significant milestone in DNA’s ongoing journey toward advancing healthcare innovation. In 2024, DNA received the Exemplary Practice Award from the Renal Physicians Association.

“Our physicians and staff strive every day to make DNA a leader in nephrology care,” said Dr. Liang. “DNA continues to pave the way for other medical groups to embrace value-based care, ensuring better patient experiences and stronger community health outcomes.”

For more information about Dallas Nephrology Associates and its award-winning care model, please visit www.dneph.com.

About Dallas Nephrology Associates

Established in 1971, Dallas Nephrology Associates (DNA), has been at the forefront of creating person-centered value-based care in Nephrology, with a focus on innovation and patient choice. For over 50 years, DNA has been a trusted source of information and education resulting in quality kidney care. DNA offers the entire spectrum of nephrology care from the office management of CKD patients, to 24/7 coverage of hospitals, dialysis clinics, as well as management of the dialysis accesses of dialysis patients through our 2 vascular centers in the Dallas Fort Worth Metroplex.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331711991/en/